Share:

Top Back to top

EBMT at the 63rd ASH Annual Meeting & Exposition

by
Research

The EBMT will be actively participating to the 63rd American Society of Hematology Meeting that will be held December 11-14, in Atlanta, Georgia, US or virtually.

The EBMT will present 23 communications in the different oral or posters sessions. You will find below the list of these abstracts including title, time and location of presentations. You can click on the title to view the full abstract from the ASH website.

Congratulations to all co-authors and thank you all for your continuous support!


Management of Steroid-Refractory Graft-Versus-Host Disease – a Survey By the Transplant Complications Working Party of the EBMT

Type: Paper
Number: 2884
Presenter: Zinaida Peric
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
Time and Location:
Sunday, December 12, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT

Type: Paper
Number: 2920
Presenter: Razan Mohty
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Time and Location:
Sunday, December 12, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Type: Paper
Number: 3952
Presenter: Xavier Poiré
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party

Type: Paper
Number: 1809
Presenter: Amin Turki
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Time and Location:
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
 

Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Type: Paper
Number: 3954
Presenter: Guillermo Ortí
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Type: Paper
Number: 2818
Presenter: Anne Mea Spanjaart
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster II
Time and Location:
Sunday, December 12, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Type: Paper
Number: 1840
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster I
Time and Location:
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
 

Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT

Type: Paper
Number: 1822
Presenter: Vivek Patel
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster I
Time and Location:
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Type: Paper
Number: 3937
Presenter: Meral Beksac
Program: Oral and Poster Abstracts
Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP)

Type: Paper
Number: 3959
Presenter: Francesco Onida
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Type: Paper
Number: 3953
Presenter: Xavier Poiré
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Type: Paper
Number: 3890
Presenter: Michele Wieczorek
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH)

Type: Paper
Number: 2866
Presenter: Diana Averbuch
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Time and Location:
Sunday, December 12, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)

Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Type: Paper
Number: 3964
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)

Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Type: Paper
Number: 1787
Presenter: Eleni Gavriilaki
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Time and Location:
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Type: Paper
Number: 2876
Presenter: Sebastian Giebel
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Time and Location:
Sunday, December 12, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study

Type: Paper
Number: 174
Presenter: Alberto Mussetti
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches and Outcomes
Time and Location:
Saturday, December 11, 2021: 12:00 PM-1:30 PM
B308-B309 (Georgia World Congress Center)
 

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Type: Paper
Number: 2862
Presenter: Andre Willasch
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Time and Location:
Sunday, December 12, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1)

Type: Paper
Number: 3910
Presenter: Mohamed Kharfan-Dabaja
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)
 

Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission

Type: Paper
Number: 1783
Presenter: Alexandros Spyridonidis
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Time and Location:
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
 

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Type: Paper
Number: 1841
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location:
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
 

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Type: Paper
Number: 485
Presenter: Nico Gagelmann
Program: Oral and Poster Abstracts
Session: 731. Autologous Transplantation: Clinical and Epidemiological I
Time and Location:
Sunday, December 12, 2021: 12:00 PM-1:30 PM
B304-B305 (Georgia World Congress Center)
 

Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Type: Paper
Number: 3916
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
Time and Location:
Monday, December 13, 2021: 6:00 PM-8:00 PM
Hall B5 (Georgia World Congress Center)